PriceTargets.com logo

Otonomy - OTIC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.25
  • Forecasted Upside: 2,776.11%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.11 As of 03/31/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for OTIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Otonomy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTIC

Analyst Price Target is $3.25
▲ +2,776.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Otonomy in the last 3 months. The average price target is $3.25, with a high forecast of $6.00 and a low forecast of $0.50. The average price target represents a 2,776.11% upside from the last price of $0.11.

This chart shows the closing price for OTIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Otonomy. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2022Piper SandlerDowngradeOverweight ➝ Neutral$3.00 ➝ $0.50Low
8/2/2022HC WainwrightDowngradeBuy ➝ NeutralLow
8/1/2022Piper SandlerLower Target$6.00 ➝ $3.00Low
4/20/2022OppenheimerBoost TargetOutperform$5.00 ➝ $6.00Medium
11/11/2021Cantor FitzgeraldReiterated RatingOverweightMedium
5/12/2021HC WainwrightReiterated RatingBuy$5.50Low
4/13/2021Piper SandlerBoost Target$5.00 ➝ $6.00High
2/23/2021HC WainwrightLower TargetBuy$10.00 ➝ $5.50Low
2/22/2021Piper SandlerLower Target$10.00 ➝ $5.00N/A
12/18/2020HC WainwrightBoost TargetPositive ➝ Buy$9.00 ➝ $10.00High
11/22/2020OppenheimerInitiated CoverageBuy$11.00Medium
8/17/2020Cantor FitzgeraldReiterated RatingOverweight$11.00High
8/6/2020HC WainwrightReiterated RatingBuy$9.00Low
7/7/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$9.00 ➝ $11.00High
7/7/2020HC WainwrightBoost TargetPositive ➝ Buy$8.00 ➝ $9.00High
7/6/2020OppenheimerReiterated RatingBuy$8.00High
6/16/2020HC WainwrightReiterated RatingBuy$8.00Low
6/16/2020Cantor FitzgeraldBoost TargetOverweight$3.00 ➝ $9.00High
6/5/2020HC WainwrightReiterated RatingBuy ➝ Market Perform$8.00Medium
5/29/2020OppenheimerInitiated CoverageBuy$8.00High
5/29/2020Craig HallumInitiated CoverageBuy$8.00High
12/24/2019OppenheimerInitiated CoverageOutperform$8.00High
11/6/2019HC WainwrightReiterated RatingBuy$8.00Medium
8/29/2019HC WainwrightInitiated CoverageBuy$8.00High
3/5/2019Piper Jaffray CompaniesReiterated RatingBuyLow
3/4/2019Cantor FitzgeraldReiterated RatingBuy$5.00High
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight$9.00Medium
8/14/2018SunTrust BanksLower TargetBuy$10.00Low
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/2/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Otonomy logo
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.11
Low: $0.11
High: $0.12

50 Day Range

MA: $0.11
Low: $0.10
High: $0.12

52 Week Range

Now: $0.11
Low: $0.06
High: $2.54

Volume

580,884 shs

Average Volume

407,938 shs

Market Capitalization

$7.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Otonomy?

The following sell-side analysts have issued research reports on Otonomy in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, and StockNews.com.
View the latest analyst ratings for OTIC.

What is the current price target for Otonomy?

2 Wall Street analysts have set twelve-month price targets for Otonomy in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 2,776.1%. Oppenheimer Holdings Inc. has the highest price target set, predicting OTIC will reach $6.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $0.50 for Otonomy in the next year.
View the latest price targets for OTIC.

What is the current consensus analyst rating for Otonomy?

Otonomy currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OTIC, but not buy more shares or sell existing shares.
View the latest ratings for OTIC.

What other companies compete with Otonomy?

Other companies that are similar to Otonomy include Graybug Vision, Aytu BioPharma, Guardion Health Sciences, Marker Therapeutics and Bright Minds Biosciences. Learn More about companies similar to Otonomy.

How do I contact Otonomy's investor relations team?

Otonomy's physical mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (619) 323-2200 and its investor relations email address is [email protected] The official website for Otonomy is www.otonomy.com. Learn More about contacing Otonomy investor relations.